Company news
Cosmo Pharmaceuticals Nv (SIX:COPN) news
Cosmo Pharmaceuticals Nv news releases on 6ix. Latest, Aug 14, 2026: Cosmo Announces SIX Ticker Symbol Change to "CMHC"
Press releases & updates
Cosmo Announces SIX Ticker Symbol Change to "CMHC"
August 14, 2026
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
July 23, 2026
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
July 1, 2026
Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany
June 15, 2026
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
June 11, 2026
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
May 18, 2026
Cosmo N : Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program (EN)
May 18, 2026
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
April 15, 2026
Voting Results of Cosmo's 2026 AGM
April 10, 2026
Cosmo Pharmaceuticals N : AGM – 10 April 2026 – Voting Results
April 9, 2026
Cosmo Pharmaceuticals N : AGM – 10 April 2026 – Minutes
April 9, 2026
Cosmo Pharmaceuticals N : AGM – 10 April 2026 – Distribution Information
April 9, 2026
Cosmo Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026
March 16, 2026
Cosmo Presents Agenda for AGM 2026
March 12, 2026
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
March 9, 2026
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
March 5, 2026
Cosmo to Participate in Upcoming Investor Conferences
February 18, 2026
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
February 3, 2026
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
January 28, 2026
Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms
January 12, 2026
Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway
December 3, 2025
Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe
December 1, 2025
Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment
November 14, 2025
Cosmo's ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability Oversight Engagement, and Italian Manufacturing Plant Awarded EcoVadis Bronze Medal
November 11, 2025
Cosmo Receives CE Certification for ColonPRO EU - The Most Advanced AI Software Platform for Colonoscopy in Europe
November 3, 2025
Cosmo Pharmaceuticals Receives Regulatory Approval by the European Commission for Winlevi(R) in the EU, Following on the Positive CHMP Opinion
October 21, 2025
Cosmo Pharmaceuticals Announces Regulatory Approval of Winlevi(R) in South Korea
October 7, 2025
Cosmo Receives Positive CHMP Opinion for Winlevi(R) for Treatment of Acne in Adults and Adolescents, Following Successful Re-Examination
August 27, 2025
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
August 8, 2025
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth Momentum
August 6, 2025
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
July 23, 2025
Cosmo Announces Launch of Winlevi(R) for Treatment of Acne in Singapore and Malaysia
July 17, 2025
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact Commitment, and Climate Action Pledge
July 16, 2025
Cosmo Unveils Bold 2030 Vision and Strategy; Launches AI-Driven Growth Phase at Investor Day 2025
July 1, 2025
Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
June 25, 2025
Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius(TM) with Apple Vision Pro at Rush University Medical Center
June 24, 2025
Voting Results of Cosmo's 2025 AGM
May 30, 2025
Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025
May 5, 2025
Cosmo Announces EU MDR Certification for Endovision's Cerebro, expanding its real-time AI ecosystem
May 2, 2025
Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)
April 29, 2025
Cosmo Receives Negative CHMP Opinion on Winlevi(R) (clascoterone Cream 1%) in Europe and Will Appeal the Decision
April 29, 2025
Cosmo Publishes Agenda of AGM 2025
April 29, 2025
Cosmo Appoints Federico Sommariva as Chief Legal Counsel
April 1, 2025
Cosmo Pharmaceuticals publishes Annual Report 2024
March 21, 2025
Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 2025
March 6, 2025